AbbVie Announces EPKINLY Listing On Ontario Health (Cancer Care Ontario) Formulary And Quebec's RAMQ For Treatment Of Relapsed Or Refractory Diffuse Large B-Cell Lymphoma In Adult Patients After Two Or More Lines Of Therapy
Portfolio Pulse from Benzinga Newsdesk
AbbVie has announced that its drug EPKINLY has been listed on Ontario Health (Cancer Care Ontario) Formulary and Quebec's RAMQ for the treatment of relapsed or refractory diffuse large B-cell lymphoma in adult patients after two or more lines of therapy.
August 15, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's drug EPKINLY has been listed on Ontario Health and Quebec's RAMQ for treating relapsed or refractory diffuse large B-cell lymphoma, which could boost its sales and market presence in Canada.
The listing of EPKINLY on major Canadian health formularies is likely to increase its sales and market penetration in Canada, positively impacting AbbVie's revenue and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
The listing of AbbVie's EPKINLY on Ontario Health and Quebec's RAMQ could have a positive impact on the Canadian healthcare sector, potentially benefiting the iShares MSCI Canada ETF (EWC).
The inclusion of a new treatment option like EPKINLY in Canadian health formularies could enhance the healthcare sector's performance, indirectly benefiting the iShares MSCI Canada ETF (EWC).
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50